Jazz Pharmaceuticals(JAZZ) - 2023 Q4 - Earnings Call Presentation

Non-GAAP Net Leverage Ratio based on non-GAAP Adjusted EBITDA1 Reconciliation of GAAP net income to Non-GAAP Adjusted EBITDA1 (calculated in accordance with the Company's Credit Agreement) and the Calculation of NonGAAP Net Leverage Ratio | --- | --- | |--------------------------------------------------------------------|--------------------| | In millions (unaudited) | LTM Ended 12/31/23 | | GAAP net income 415 | | | Interest expense, net | 289 | | Income tax benefit (120) | | | Depreciation and amortizati ...